Atypical hearing loss in women with breast cancer receiving adjuvant treatment

Jenkins, V, Beveridge, H, Low, R and Mitra, S (2006) Atypical hearing loss in women with breast cancer receiving adjuvant treatment. Breast, 15 (3). pp. 448-51. ISSN 0960-9776

Full text not available from this repository.

Abstract

There are no reports of adjuvant treatments for early breast cancer causing hearing loss. Yet in this exploratory study 14/16 women who had received Fluorouracil, Epirubicin and Cyclophosphamide (FEC) chemotherapy regimen, 11 of whom also received endocrine treatment, had reduced hearing sensitivity, with 9/16 being atypical. It is not clear whether this finding is related to oestrogen reduction and/or ototoxicity but a more detailed investigation in this area is warranted given the large number of women with breast cancer who receive adjuvant treatments.

Item Type: Article
Additional Information: Journal Article Research Support, Non-U.S. Gov't Scotland
Keywords: Adult Antineoplastic Combined Chemotherapy Protocols/*adverse effects Audiometry, Pure-Tone Breast Neoplasms/*drug therapy Chemotherapy, Adjuvant Female Hearing Loss/*chemically induced Humans Middle Aged Pilot Projects
Schools and Departments: Brighton and Sussex Medical School > Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Subjects: R Medicine
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens
R Medicine > RG Gynecology and obstetrics > RG0491 Diseases of the breast
Related URLs:
Depositing User: Tracy Woodcock
Date Deposited: 17 Apr 2012 11:47
Last Modified: 26 Jun 2012 13:33
URI: http://sro.sussex.ac.uk/id/eprint/38595
📧 Request an update